BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27834948)

  • 1. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.
    Pan XY; Liu XJ; Li J; Zhen SJ; Liu DX; Feng Q; Zhao WX; Luo Y; Zhang YL; Li HW; Yang JL
    Gene Ther; 2017 Jan; 24(1):40-48. PubMed ID: 27834948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo.
    Yang JL; Pan XY; Zhao WX; Hu QC; Ding F; Feng Q; Li GY; Luo Y
    Int J Oncol; 2016 Mar; 48(3):1218-28. PubMed ID: 26780944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
    Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
    J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues.
    Yang JL; Liu DX; Zhen SJ; Zhou YG; Zhang DJ; Yang LY; Chen HB; Feng Q
    BMC Cancer; 2016 Feb; 16():131. PubMed ID: 26897358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
    Liu FR; Bai S; Feng Q; Pan XY; Song SL; Fang H; Cui J; Yang JL
    BMC Cancer; 2018 Nov; 18(1):1087. PubMed ID: 30419845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells.
    Qian J; Yang M; Feng Q; Pan XY; Yang LL; Yang JL
    Exp Biol Med (Maywood); 2021 May; 246(10):1228-1238. PubMed ID: 33535808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.
    Wang P; Pan X; Feng Q; Zou H; Cui J; He Y; Luo Y; Yang J
    Immunotherapy; 2020 Aug; 12(12):879-890. PubMed ID: 32664770
    [No Abstract]   [Full Text] [Related]  

  • 8. RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
    Huang CC; Liu FR; Feng Q; Pan XY; Song SL; Yang JL
    BMC Cancer; 2021 Mar; 21(1):321. PubMed ID: 33765976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.
    Lin P; Qian J; Huang CC; Xu WM; Wang YY; Gao ZR; Zheng SQ; Wang P; Jia DQ; Feng Q; Yang JL
    BMC Cancer; 2024 Jan; 24(1):71. PubMed ID: 38216883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.
    Yu T; Shi Y; Pan X; Feng Q; Wang P; Song S; Yang L; Yang J
    PLoS One; 2022; 17(6):e0269084. PubMed ID: 35648774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains.
    Cochet O; Kenigsberg M; Delumeau I; Duchesne M; Schweighoffer F; Tocqué B; Teillaud JL
    Mol Immunol; 1998 Dec; 35(17):1097-110. PubMed ID: 10395199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer.
    Dai F; Zhang PB; Feng Q; Pan XY; Song SL; Cui J; Yang JL
    J Cancer; 2021; 12(9):2768-2776. PubMed ID: 33854636
    [No Abstract]   [Full Text] [Related]  

  • 18. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
    Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
    Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.